Homology Modeling and Molecular Docking Studies on Type II Diabetes Complications Reduced PPARγ Receptor with Various Ligand Molecules by Prabhu, S. et al.
Biomedicine & Pharmacotherapy 92 (2017) 528–535Original article
Homology modeling and molecular docking studies on Type II diabetes
complications reduced PPARg receptor with various ligand molecules
S. Prabhua, S. Vijayakumara,*, P. Manogara, Gaanty Pragas Maniamb,c,
Natanamurugaraj Govindanb
aComputational Phytochemistry Lab, PG and Research Department of Botany and Microbiology, AVVM Sri Pushpam College (Autonomous) Poondi, Thanjavur
(Dist), Tamil Nadu, India
b Faculty of Industrial Sciences and Technology, Universiti Malaysia Pahang, Lebuhraya Tun Razak, 26300 Gambang, Kuantan, Pahang, Malaysia
cCentral Laboratory Universiti Malaysia Pahang, Lebuhraya Tun Razak, 26300 Gambang, Kuantan, Pahang, Malaysia
A R T I C L E I N F O
Article history:
Received 6 December 2016
Received in revised form 13 May 2017
Accepted 17 May 2017
Keywords:
Type II diabetes
PPARg
Homology modeling
Molecular docking
Ligand molecules
A B S T R A C T
Peroxisome proliferator-activated receptor gamma (PPARg), a type II nuclear receptor present in adipose
tissue, colon and macrophages. It reduces the hyperglycemia associated metabolic syndromes.
Particularly, type II diabetes-related cardiovascular system risk in human beings. The fatty acid storage
and glucose metabolism are regulated by PPARg activation in human body. According to recent reports
commercially available PPARg activating drugs have been causing severe side effects. At the same time,
natural products have been proved to be a promising area of drug discovery. Recently, many studies have
been attempted to screen and identify a potential drug candidate to activate PPARg. Hence, in this study
we have selected some of the bio-active molecules from traditional medicinal plants. Molecular docking
studies have been carried out against the target, PPARg. We Results suggested that Punigluconin has a
efﬁcient docking score and it is found to have good binding afﬁnities than other ligands. Hence, we
concluded that Punigluconin is a better drug candidate for activation of PPARg gene expression. Further
studies are necessary to conﬁrm their efﬁcacy and possibly it can develop as a potential drug in future.
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